Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

Inclusion Criteria

• •biopsy proven adenocarcinoma of the colon or rectum and synchronous or metachronous peritoneal carcinomatosis.
• •absence of systemic disease, with the exception of small, superficial liver metastases, requiring only minor surgery.
• •resectable disease at staging, during laparoscopic evaluation and during exploration for cytoreductive surgery and intraperitoneal chemotherapy.
• •complete macroscopic cytoreduction at the time of surgery (CC-0/1)
• •good general health status (Karnofsky index \> 70%)
• •expected life expectancy more than 6 months
• •no other malignancy than disease under study
• •serum creatinine \< 1.5 mg/dl or a calculated GFR ≥ 60 mL/min/1.73 m
• •serum total bilirubin \< 1.5 mg/dl
• •platelet count \> 100,000/ml
• •hemoglobin \> 9g/dl
• •neutrophil granulocytes \> 1,500/ml
• •International Normalized Ration (INR) 2 or \< 2
• •Absence of alcohol and/or drug abuse
• •No inclusion in other clinical trials interfering with the study protocol
• •No concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol
• •Absence of heart failure (NYHA 2 or \> 2) or significant coronary artery disease
• •No pregnancy or breast feeding
• •Adequate contraception in fertile patients